Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, before surgery in patients with high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. The cli.